摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-[(S)-5-(2-amino-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one | 1220979-20-3

中文名称
——
中文别名
——
英文名称
6-[(S)-5-(2-amino-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one
英文别名
(5S)-5-(2-aminoethyl)-3-(3-oxo-4H-1,4-benzothiazin-6-yl)-1,3-oxazolidin-2-one
6-[(S)-5-(2-amino-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-one化学式
CAS
1220979-20-3
化学式
C13H15N3O3S
mdl
——
分子量
293.346
InChiKey
UFTCBKDCPYVACN-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    20
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    110
  • 氢给体数:
    2
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    描述:
    6-[(S)-5-(2-amino-ethyl)-2-oxo-oxazolidin-3-yl]-4H-benzo[1,4]thiazin-3-onetoluene-4-sulfonic acid (R)-4-hydroxy-7-oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de][1,5]naphthyridin-4-ylmethyl esterpotassium carbonate 作用下, 以 乙醇 为溶剂, 反应 72.0h, 以26%的产率得到(S)-4-hydroxy-4-({2-[(S)-2-oxo-3-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-oxazolidin-5-yl]-ethylamino}-methyl)-4,5-dihydro-pyrrolo[3,2,1-de][1,5]naphthyridin-7-one
    参考文献:
    名称:
    [EN] TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS
    [FR] COMPOSÉS ANTIBIOTIQUES OXAZOLIDINONE TRICYCLIQUE
    摘要:
    该发明涉及式(I)的抗菌化合物,其中“-----”是键或不存在,V是CH,CR 6或N; R 0是H或如果“-----”是键,则也可以是烷氧基; R 1主要是H或卤素; 当“-----”是键时,U是CH或N,或者如果“-----”不存在,则U是CH 2,NH或NR 9; R 2是H,烷基羰基或-CH 2 -R 3; R 3是H,烷基或羟基烷基; R 4是H或如果n不为0且R 5为H,则也可以是OH; R 5是H,烷基,羟基烷基,氨基烷基,烷氧基烷基,羧基或烷氧羰基; R 6是羟基烷基,羧基,烷氧羰基或-(CH 2 ) q -NR 7 R 8,其中q为1、2或3,且R 7和R 8中的每一个独立地是H或烷基,或R 7和R 8与携带它们的N原子形成一个环; R 9是烷基或羟基烷基; A是-(CH 2 ) p-,-CH 2 CH 2 CH(OH)-或-COCH 2 CH(OH)-; G是取代苯基或G 1或G 2,其中Q是O或S,X是CH或N; Y 1、Y 2和Y 3每个可以是CH或N; 当A为-CH 2 CH 2 CH(OH)-或-COCH 2 CH(OH)-时,n为0,当A为-(CH 2 ) p-,p为1、2、3或4时,n为0、1或2,但n和p的总和为2、3或4; 以及这些化合物的盐。
    公开号:
    WO2010041194A1
点击查看最新优质反应信息

文献信息

  • [EN] ANTIBACTERIAL BIAROMATIC DERIVATIVES<br/>[FR] DÉRIVÉS BI-AROMATIQUES ANTIBACTÉRIENS
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2014170821A1
    公开(公告)日:2014-10-23
    The invention relates to antibacterial compounds of formula I (I) wherein R is H, cyano, alkoxy, cyanomethoxy, cycloalkylmethoxy, hydroxyalkoxy, alkoxyalkoxy, alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (l-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-l-yl or 3,4-dihydroxycyclopentyl)methoxy; U1 is N or CR1, U2 is N or CR2, U3 is N or CR3 and U4 is N or CR4, it being understood that at most three of U1, U2, U3 and U4 can be N at the same time; V1 is N or CR5, V2 is N or CR6, V3 is N or CR7 and V4 is N or CH, it being understood that at most two of V1, V2, V3 and V4 can be N at the same time; R1 is H, cyano, hydroxy or alkoxy; R2 is H, hydroxy or alkoxy; R3 is H, cyano, hydroxy, alkoxy or carboxamido; R4 is H or alkoxy; R5 is H, hydroxy or halogen; R6 is H, hydroxy or halogen; R7 is H; the dotted line "_____ " represents a bond or is absent; W represents CH or N when the dotted line "_____ " is a bond, or W represents CH2 when the dotted line "_____ " is absent; X represents CH or N; and Q represents O or S; and salts thereof.
    该发明涉及公式I(I)的抗菌化合物,其中R是H、基、烷氧基、甲氧基、环烷基甲氧基、羟基烷氧基、烷氧基烷氧基、烷氧基羰基、2-乙氧基-2-氧基乙氧基、2-(甲基基)-2-氧基乙氧基、(1-环丁基)甲氧基、3-羟基吡咯烷-1-基或3,4-二羟基环戊基)甲氧基;U1是N或CR1,U2是N或CR2,U3是N或CR3,U4是N或CR4,理解为U1、U2、U3和U4中最多有三个可以同时为N;V1是N或CR5,V2是N或CR6,V3是N或CR7,V4是N或CH,理解为V1、V2、V3和V4中最多有两个可以同时为N;R1是H、基、羟基或烷氧基;R2是H、羟基或烷氧基;R3是H、基、羟基、烷氧基或羧胺基;R4是H或烷氧基;R5是H、羟基或卤素;R6是H、羟基或卤素;R7是H;虚线"_____"代表键或不存在;W代表CH或N,当虚线"_____"为键时,或W代表CH2,当虚线"_____"不存在时;X代表CH或N;Q代表O或S;及其盐。
  • TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS
    申请人:Hubschwerlen Christian
    公开号:US20110195961A1
    公开(公告)日:2011-08-11
    The invention relates to antibacterial compounds of formula I wherein is a bond or is absent, V is CH, CR 6 or N; R 0 is H or, if is a bond, may also be alkoxy; R 1 is notably H or halogen; U is CH or N when is a bond, or, if is absent, U is CH 2 , NH or NR 9 ; R 2 is H, alkylcarbonyl or —CH 2 —R 3 ; R 3 is H, alkyl or hydroxyalkyl; R 4 is H or, if n is not 0 and R 5 is H, may also be OH; R 5 is H, alkyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, carboxy or alkoxycarbonyl; R 6 is hydroxyalkyl, carboxy, alkoxycarbonyl or —(CH 2 ) q —NR 7 R 8 , q being 1, 2 or 3 and each of R 7 and R 8 independently being H or alkyl or R 7 and R 8 forming with the N atom bearing them a ring; R 9 is alkyl or hydroxyalkyl; A is —(CH 2 ) p —, —CH 2 CH 2 CH(OH)— or —COCH 2 CH(OH)—; G is substituted phenyl or G 1 or G 2 wherein Q is O or S and X is CH or N; and Y 1 , Y 2 and Y 3 may each be CH or N; and n is 0 when A is —CH 2 CH 2 CH(OH)— or —COCH 2 CH(OH)—, and n is 0, 1 or 2 when A is —(CH 2 ) p —, p being 1, 2, 3 or 4, with the proviso that the sum of n and p is then 2, 3 or 4; and to salts of such compounds.
    该发明涉及式I的抗菌化合物,其中: - 当V为CH或N时,U为CH或N,R1为H或卤素,R2为H、烷基羰基或—CH2—R3,R3为H或烷基羟基,R4为H或OH(当n不为0且R5为H时),R5为H、烷基、羟基烷基、基烷基、烷氧基烷基、羧基或烷氧羰基,R6为羟基烷基、羧基、烷氧羰基或—( )q—NR7R8,其中q为1、2或3,且R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环; - 当V为CR6时,U为 、NH或NR9,R0为H或烷氧基,R1为H或卤素,R2为H、烷基羰基或— —R3,R3为H或烷基羟基,R4为H或OH(当n不为0且R5为H时),R5为H、烷基、羟基烷基、基烷基、烷氧基烷基、羧基或烷氧羰基,R6为羟基烷基、羧基、烷氧羰基或—( )q—NR7R8,其中q为1、2或3,且R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环; - 当V为一条键时,U为CH或N,R0为H或烷氧基,R1为H或卤素,R2为H、烷基羰基或— —R3,R3为H或烷基羟基,R4为H或OH(当n不为0且R5为H时),R5为H、烷基、羟基烷基、基烷基、烷氧基烷基、羧基或烷氧羰基,R6为羟基烷基、羧基、烷氧羰基或—( )q—NR7R8,其中q为1、2或3,且R7和R8各自独立地为H或烷基,或者R7和R8与它们所带的N原子形成一个环;A为—( )p—、— CH(OH)—或—CO CH(OH)—,G为取代苯基或G1或G2,其中Q为O或S,X为CH或N,Y1、Y2和Y3各自可以为CH或N;n当A为— CH(OH)—或—CO CH(OH)—时为0,当A为—( )p—时,n为0、1或2,p为1、2、3或4,但n和p的和必须为2、3或4;以及这些化合物的盐。
  • Antibacterial Biaromatic Derivatives
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:US20160075722A1
    公开(公告)日:2016-03-17
    The invention relates to antibacterial compounds of formula I (I) wherein R is H, cyano, alkoxy, cyanomethoxy, cycloalkylmethoxy, hydroxyalkoxy, alkoxyalkoxy, alkoxycarbonyl, 2-ethoxy-2-oxoethoxy, 2-(methylamino)-2-oxoethoxy, (1-cyanocyclobutyl)methoxy, 3-hydroxy-pyrrolidin-1-yl or 3,4-dihydroxycyclopentyl)methoxy; U 1 is N or CR 1 , U 2 is N or CR 1 , U 3 is N or CR 3 and U 4 is N or CR 1 , it being understood that at most three of U 1 , U 2 , U 3 and U 4 can be N at the same time; V 1 is N or CR 5 , V 2 is N or CR 6 , V 3 is N or CR 7 and V 4 is N or CH, it being understood that at most two of V 1 , V 2 , V 3 and V4 can be N at the same time; R1 is H, cyano, hydroxy or alkoxy; R2 is H, hydroxy or alkoxy; R 3 is H, cyano, hydroxy, alkoxy or carboxamido; R 4 is H or alkoxy; R 5 is H, hydroxy or halogen; R 6 is H, hydroxy or halogen; R 7 is H; the dotted line “______” represents a bond or is absent; W represents CH or N when the dotted line “______” is a bond, or W represents CH 2 when the dotted line “______” is absent; X represents CH or N; and Q represents O or S; and salts thereof.
    本发明涉及式I的抗菌化合物(I),其中R为H,基,烷氧基,甲氧基,环烷基甲氧基,羟基烷氧基,烷氧基烷氧基,烷氧基羧酰基,2-乙氧基-2-氧代乙氧基,2-(甲基基)-2-氧代乙氧基,(1-环丁基)甲氧基,3-羟基吡咯烷-1-基或3,4-二羟基环戊基)甲氧基;U1为N或CR1,U2为N或CR1,U3为N或CR3,U4为N或CR1,其中最多只能同时有三个U1,U2,U3和U4为N;V1为N或CR5,V2为N或CR6,V3为N或CR7,V4为N或CH,其中最多只能同时有两个V1,V2,V3和V4为N;R1为H,基,羟基或烷氧基;R2为H,羟基或烷氧基;R3为H,基,羟基,烷氧基或羧酰胺基;R4为H或烷氧基;R5为H,羟基或卤素;R6为H,羟基或卤素;R7为H;虚线“______”表示键或不存在;当虚线“______”为键时,W表示CH或N,当虚线“______”不存在时,W表示CH2;X表示CH或N;Q表示O或S;以及其盐。
  • ANTIBACTERIAL BIAROMATIC DERIVATIVES
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:EP2986607A1
    公开(公告)日:2016-02-24
  • ANTIBACTERIAL BASIC BIAROMATIC DERIVATIVES WITH AMINOALKOXY SUBSTITUTION
    申请人:Idorsia Pharmaceuticals Ltd
    公开号:EP3207042B1
    公开(公告)日:2018-10-03
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)